

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8081115

| | |
|---|--|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| ARS PHARMACEUTICALS, INC. | 04/30/2020 |
| RECEIVING PARTY DATA | |
| Name: | AEGIS THERAPEUTICS, LLC |
| Street Address: | 3430 CARMEL MOUNTAIN ROAD |
| City: | SAN DIEGO |
| State/Country: | CALIFORNIA |
| Postal Code: | 92121 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 18206881 |
| CORRESPONDENCE DATA | |
| Fax Number: | (866)974-7329 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 650-493-9300 |
| Email: | patentdocket@wsgr.com, ljayme@wsgr.com |
| Correspondent Name: | WILSON SONSINI GOODRICH & ROSATI |
| Address Line 1: | 650 PAGE MILL ROAD |
| Address Line 4: | PALO ALTO, CALIFORNIA 94304-1050 |
| ATTORNEY DOCKET NUMBER: | 55358-701.308 |
| NAME OF SUBMITTER: | LEA R. JAYME |
| SIGNATURE: | /Lea R. Jayme/ |
| DATE SIGNED: | 07/27/2023 |
| Total Attachments: 1 | |
| source=55358-701.308 ARS to Aegis (3)#page1.tif | |

CORPORATE TO CORPORATE ASSIGNMENT

Docket Numbers 55358-701.301, 55358-701.302, 55358-701.303

WHEREAS, ARS Pharmaceuticals Inc., a corporation incorporated under the laws of the state Delaware, having a place of business at 8195 Run of the Knolls Ct., San Diego, CA 92127 (hereinafter "Assignor"), and Aegis Therapeutics, LLC, a corporation incorporated under the laws of the state of California, having a place of business at 3430 Carmel Mountain Road, Suite 300, San Diego, CA 92121 (hereinafter "Assignee"), together own the entire right, title and interest in and to the inventions disclosed in the following Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE

- for which application serial number 16/420,034, a U.S. Continuation Application of PCT/US2019/016918 filed on February 06, 2019 in the U.S. Receiving Office of the Patent Cooperation Treaty, was filed on May 22, 2019 in the United States Patent and Trademark Office;
- for which application serial number 16/420,044, a U.S. Continuation Application of PCT/US2019/016918 filed on February 06, 2019 in the U.S. Receiving Office of the Patent Cooperation Treaty, was filed on May 22, 2019 in the United States Patent and Trademark Office;
- for which application serial number 16/420,051, a U.S. Continuation Application of PCT/US2019/016918 filed on February 06, 2019 in the U.S. Receiving Office of the Patent Cooperation Treaty, was filed on May 22, 2019 in the United States Patent and Trademark Office;


WHEREAS, Assignor desires to assign, and Assignee desires to acquire all of Assignor's right, title and interest in and to the Application(s), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee its entire right, title and interest (a) in and to said Inventions; (b) in and to said Application(s), including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).
2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States. Such cooperation by Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon Assignor, its successors, assigns and other legal representatives.
4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. Said Assignor hereby requests that any Patent(s) issuing in the United States be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.
6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.
ASSIGNOR: **ARS PHARMACEUTICALS INC.**

Date: 30 April 2020

By: 
Name: Richard Lowenthal
Title: President and Chief Executive Officer

RECEIVED AND AGREED TO BY ASSIGNEE:
AEGIS THERAPEUTICS, LLC

Date: April 30, 2020

By: 
Name: Craig C. Chambliss
Title: President and Chief Executive Officer